Clinical Publications & Research Center The Role of GCH1 Deficiency and Tetrahydrobiopterin in Mental Health Publications Treatment-resistant mental health concerns significantly contribute to society in terms of financial costs and individually by creating emotional and functional costs. An important yet little-recognized cause of treatment-resistant mental health conditions is tetrahydrobiopterin (BH4) deficiency. BH4 is an essential cofactor for producing serotonin, dopamine, norepinephrine, and nitric oxide—molecules critical to mood and focus. Genomics as a Clinical Decision Support Tool for Identifying and Addressing Modifiable Causes of Cognitive Decline Publications The landscape of therapeutics for mild cognitive impairment and dementia is quite limited. While many single-agent trials of pharmaceuticals have been conducted, these trials have repeatedly been unable to show improvement in cognition. Genomics as a Clinical Decision Support Tool for Improved ASD Outcomes White Paper Considerable evidence is emerging that Autism Spectrum Disorder (ASD) is most often triggered by a range of different genetic variants that interact with environmental factors such as exposures to toxicants and changes to the food supply. Utilizing Genomically Targeted Molecular Data to Improve Patient-Specific Outcomes in Autism Spectrum Disorder White Paper Molecular biology combined with genomics can be a powerful tool for developing potential intervention strategies for improving outcomes in children with autism spectrum disorders (ASD). A Precision Medicine Approach to Alzheimer’s Disease Effective therapeutics for Alzheimer’s disease are needed. However, previous clinical trials have pre-determined a single treatment modality, such as a drug candidate or therapeutic procedure, which may be unrelated to the primary drivers of the neurodegenerative process. Translating the Science of NutriGenomics Into Practice White Paper Personalized Nutrition: Translating the Science of NutriGenomics Into Practice: Proceedings From the 2018 American College of Nutrition Meeting Genomics of Detoxification: How Genomics can be Used for Targeting Potential Intervention and Prevention Strategies Including Nutrition for Environmentally Acquired Illness White Paper Genomics of Detoxification: How Genomics can be Used for Targeting Potential Intervention and Prevention Strategies Including Nutrition for Environmentally Acquired Illness Reversal of Cognitive Decline: 100 Patients White Paper Reversal of Cognitive Decline: 100 Patients Clinical Research Announcements IntellxxDNA Powers Groundbreaking Child Health Study Alongside Documenting Hope IntellxxDNA™, a leader in genomic insights, is thrilled to announce a partnership with Documenting Hope, the research arm of Epidemic Answers, a 501(c)(3) nonprofit dedicated to helping children heal from chronic health conditions. IntellxxDNA’s Innovative Memory and Genomics Decision-Making Tool Study Gains IRB Approval IntellxxDNA™ stands as a leader, offering actionable genomic insights that can help prevent and reverse the symptoms of cognitive decline through precision genomic medicine.
The Role of GCH1 Deficiency and Tetrahydrobiopterin in Mental Health Publications Treatment-resistant mental health concerns significantly contribute to society in terms of financial costs and individually by creating emotional and functional costs. An important yet little-recognized cause of treatment-resistant mental health conditions is tetrahydrobiopterin (BH4) deficiency. BH4 is an essential cofactor for producing serotonin, dopamine, norepinephrine, and nitric oxide—molecules critical to mood and focus.
Genomics as a Clinical Decision Support Tool for Identifying and Addressing Modifiable Causes of Cognitive Decline Publications The landscape of therapeutics for mild cognitive impairment and dementia is quite limited. While many single-agent trials of pharmaceuticals have been conducted, these trials have repeatedly been unable to show improvement in cognition.
Genomics as a Clinical Decision Support Tool for Improved ASD Outcomes White Paper Considerable evidence is emerging that Autism Spectrum Disorder (ASD) is most often triggered by a range of different genetic variants that interact with environmental factors such as exposures to toxicants and changes to the food supply.
Utilizing Genomically Targeted Molecular Data to Improve Patient-Specific Outcomes in Autism Spectrum Disorder White Paper Molecular biology combined with genomics can be a powerful tool for developing potential intervention strategies for improving outcomes in children with autism spectrum disorders (ASD).
A Precision Medicine Approach to Alzheimer’s Disease Effective therapeutics for Alzheimer’s disease are needed. However, previous clinical trials have pre-determined a single treatment modality, such as a drug candidate or therapeutic procedure, which may be unrelated to the primary drivers of the neurodegenerative process.
Translating the Science of NutriGenomics Into Practice White Paper Personalized Nutrition: Translating the Science of NutriGenomics Into Practice: Proceedings From the 2018 American College of Nutrition Meeting
Genomics of Detoxification: How Genomics can be Used for Targeting Potential Intervention and Prevention Strategies Including Nutrition for Environmentally Acquired Illness White Paper Genomics of Detoxification: How Genomics can be Used for Targeting Potential Intervention and Prevention Strategies Including Nutrition for Environmentally Acquired Illness
IntellxxDNA Powers Groundbreaking Child Health Study Alongside Documenting Hope IntellxxDNA™, a leader in genomic insights, is thrilled to announce a partnership with Documenting Hope, the research arm of Epidemic Answers, a 501(c)(3) nonprofit dedicated to helping children heal from chronic health conditions.
IntellxxDNA’s Innovative Memory and Genomics Decision-Making Tool Study Gains IRB Approval IntellxxDNA™ stands as a leader, offering actionable genomic insights that can help prevent and reverse the symptoms of cognitive decline through precision genomic medicine.
